Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
GLMD moved a median of -1.80% 30 minutes after news, and -1.25% by the close. How GLMD actually reacts to news — the realized, point-in-time move the market made, measured across 159 labeled events over the last three years with zero look-ahead.
GLMD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.84% | 25% | 150 |
| 30-min | -1.80% | 36% | 155 |
| 60-min | 0.00% | 46% | 159 |
| to close | -1.25% | 42% | 158 |
| Middle 50% of GLMD reactions | -3.07% to +1.76% |
|---|---|
| Median reaction (30-min) | -1.80% |
| Measured reactions | 159 |
Half of all Galmed Pharmaceuticals Ltd. - Ordinary Shares news events land between -3.07% and +1.76% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GLMD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GLMD's baseline. Nothing else.
Recent GLMD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Galmed Pharmaceuticals For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | -2.30% | +18.41% | |
| Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation | Press release | PR Newswire | -2.30% | +18.41% | |
| Form 6-K Galmed Pharmaceuticals For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.39% | |
| Form EFFECT Galmed Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | — | -0.77% | |
| Form 6-K Galmed Pharmaceuticals For: Sep 03 | SEC filing · Form 6-K | SEC EDGAR | — | -0.77% | |
| Form 6-K Galmed Pharmaceuticals For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -3.70% | -3.21% | |
| Form 6-K Galmed Pharmaceuticals For: Sep 02 | SEC filing · Form 6-K | SEC EDGAR | -3.70% | -3.21% | |
| Form POS AM Galmed Pharmaceuticals | SEC filing · Form POS | SEC EDGAR | -3.70% | -3.21% | |
| Form 6-K Galmed Pharmaceuticals For: Aug 19 | SEC filing · Form 6-K | SEC EDGAR | -3.35% | -11.34% | |
| Form 6-K/A Galmed Pharmaceuticals For: Jul 22 | SEC filing · Form 6-K | SEC EDGAR | -1.75% | +0.00% | |
| Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology | Press release | PR Newswire | -3.35% | -11.34% | |
| Form 6-K Galmed Pharmaceuticals For: Aug 17 | SEC filing · Form 6-K | SEC EDGAR | +4.85% | -1.27% | |
| Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models | Press release | PR Newswire | +4.85% | -1.27% | |
| Form 6-K Galmed Pharmaceuticals For: Aug 14 | SEC filing · Form 6-K | SEC EDGAR | +4.85% | -1.27% | |
| Form 6-K Galmed Pharmaceuticals For: Jul 31 | SEC filing · Form 6-K | SEC EDGAR | -2.97% | -4.60% | |
| Form 6-K Galmed Pharmaceuticals For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +10.74% | |
| Form 6-K Galmed Pharmaceuticals For: Jul 28 | SEC filing · Form 6-K | SEC EDGAR | -6.99% | +0.94% | |
| Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market | Press release | PR Newswire | -6.99% | +0.94% | |
| Form 6-K Galmed Pharmaceuticals For: Jul 22 | SEC filing · Form 6-K | SEC EDGAR | — | +12.88% | |
| Form 6-K Galmed Pharmaceuticals For: Jul 16 | SEC filing · Form 6-K | SEC EDGAR | -6.12% | +0.86% | |
| Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol | Press release | PR Newswire | -6.12% | +0.86% | |
| Form 6-K Galmed Pharmaceuticals For: Jul 08 | SEC filing · Form 6-K | SEC EDGAR | -0.09% | +2.06% | |
| Form 6-K Galmed Pharmaceuticals For: Jun 22 | SEC filing · Form 6-K | SEC EDGAR | -0.84% | +2.56% | |
| Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition | Press release | PR Newswire | -0.84% | +2.56% | |
| Form 6-K Galmed Pharmaceuticals For: Jun 08 | SEC filing · Form 6-K | SEC EDGAR | -3.88% | -20.87% | |
| Form POS EX Galmed Pharmaceuticals | SEC filing · Form POS | SEC EDGAR | -3.88% | -20.87% | |
| Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market | Press release | PR Newswire | -3.88% | -20.87% | |
| Form 6-K Galmed Pharmaceuticals For: Jun 02 | SEC filing · Form 6-K | SEC EDGAR | +2.01% | -6.01% | |
| Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis | Press release | PR Newswire | +2.01% | -6.01% | |
| Form 6-K Galmed Pharmaceuticals For: May 14 | SEC filing · Form 6-K | SEC EDGAR | -1.71% | +13.53% | |
| Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg | Press release | PR Newswire | -1.71% | +13.53% | |
| Form 6-K Galmed Pharmaceuticals For: May 06 | SEC filing · Form 6-K | SEC EDGAR | — | +6.41% | |
| Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics | Press release | PR Newswire | — | +6.41% | |
| Form 6-K Galmed Pharmaceuticals For: Apr 14 | SEC filing · Form 6-K | SEC EDGAR | -5.03% | -12.04% | |
| Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers | Press release | PR Newswire | -5.03% | -12.04% | |
| Form 6-K Galmed Pharmaceuticals For: Apr 09 | SEC filing · Form 6-K | SEC EDGAR | -10.96% | -31.12% | |
| Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol | Press release | PR Newswire | -10.96% | -31.12% | |
| Form EFFECT Galmed Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +1.89% | |
| Form 20-F Galmed Pharmaceuticals For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | +0.97% | |
| Form POS AM Galmed Pharmaceuticals | SEC filing · Form POS | SEC EDGAR | +0.00% | +0.97% | |
| Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 | Press release | PR Newswire | +0.00% | +0.97% | |
| Form 6-K Galmed Pharmaceuticals For: Mar 05 | SEC filing · Form 6-K | SEC EDGAR | -0.79% | +3.94% | |
| Form 6-K Galmed Pharmaceuticals For: Mar 04 | SEC filing · Form 6-K | SEC EDGAR | — | +8.25% | |
| Form 6-K Galmed Pharmaceuticals For: Feb 09 | SEC filing · Form 6-K | SEC EDGAR | -0.53% | -3.32% | |
| Form 6-K Galmed Pharmaceuticals For: Jan 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -5.79% | |
| Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification | Press release | PR Newswire | +0.00% | -5.79% | |
| Form 6-K Galmed Pharmaceuticals For: Dec 08 | SEC filing · Form 6-K | SEC EDGAR | +0.89% | +8.04% | |
| Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting | Press release | PR Newswire | +0.89% | +8.04% | |
| Form 6-K Galmed Pharmaceuticals For: Dec 04 | SEC filing · Form 6-K | SEC EDGAR | -1.35% | +1.80% | |
| Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH | Press release | PR Newswire | -1.35% | +1.80% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GLMD section they belong to.
Where else GLMD is measured.
GLMD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) | 159 | -1.17% | 27% |
| DURECT Corporation (DRRX) | 159 | +0.03% | 51% |
| GT Biopharma, Inc. (GTBP) | 159 | -0.91% | 32% |
| ImmuCell Corporation (ICCC) | 159 | 0.00% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Galmed Pharmaceuticals Ltd. - Ordinary Shares's median reaction calculated?
Every labeled GLMD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 159 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of GLMD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GLMD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.